Search anything
Ctrl+K
Welcome to Multibagg AI
Log in to access personalized features
Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Latest stock market news, company updates, and price movements. Stay updated with market trends, earnings insights, and investment analysis.
Route Mobile posted FY26 revenue of ₹4,408.21 crore and PAT of ₹256.94 crore, announced a ₹2 final dividend, and outlined FY27 growth and margin guidance.
Route Mobile reported Q3 FY26 revenue of INR 11,071 million, higher profitability and a leadership transition, while highlighting a shift away from lower-margin ILD volumes.
Lenskart shares are in focus as a six-month lock-in ends on May 8, making 60% equity tradable amid reports of discounted block deals.
Indian benchmarks swung with US-Iran headlines as crude prices moved sharply, banks led index gains, and GIFT Nifty and global markets pointed to continued near-term volatility.
Lenskart Solutions is in focus as a six-month lock-in ends on May 8, making 60% equity tradable, alongside a potential block deal at a discount.
Online debate has revived ICAI’s optional joint ITR idea for spouses, including an illustrative ₹8 lakh nil slab and discussions on higher surcharge thresholds.
Biocon reported FY26 consolidated revenue of ₹16,927 crore and profit of ₹1,429 crore, while its board recommended a ₹0.50 dividend and cleared a 2% BBL stake buy.
Biocon reported Q4FY26 total income of ₹4,569 crore and FY26 total income of ₹17,270 crore, with EBITDA margins of 23% and 22%, respectively.
Biocon’s board approved FY26 audited results, recommended a 10% final dividend, and cleared steps to buy the remaining Biocon Biologics stake via a share-swap process.
Biocon reported FY26 audited results, recommended a 10% final dividend of ₹0.50 per share with July 3 record date, and approved steps to integrate and increase its Biocon Biologics stake.
Biocon’s board approved FY26 audited results, recommended a 10% final dividend, and cleared a plan to buy about 2% more in Biocon Biologics to make it wholly owned.
Biocon’s May 7, 2026 board meeting approved audited FY26 results, a 10% final dividend, steps to buy remaining BBL stake, new auditors, and AGM timelines.
Biocon’s board approved audited FY26 results, recommended a ₹0.50 final dividend, and cleared a ₹330.73 crore preferential issue to buy about 2% of Biocon Biologics.
Biocon reported FY26 consolidated revenue of ₹16,927 crore and profit of ₹1,429 crore, while the board proposed a 10% dividend and a 2% BBL stake buy.
Kennametal India’s board declared an interim dividend of ₹40 per share for FY26, set May 15, 2026 as the record date, and May 8, 2026 as voting cut-off.
Kennametal India posted 39% year-on-year Q4FY26 revenue growth to ₹403.1 crore and declared a ₹40 per share interim dividend after its May 7, 2026 board meeting.
